“Experts say the public’s disinterest in the latest Covid shots is likely a combination of poor messaging from authorities, a diminishing fear about a virus that three years ago was wholly unknown, and the political polarization of the pandemic itself. But whatever the reasons, that vaccine ambivalence still poses a health threat.
Elderly people and very young infants continue to have a higher chance than the rest of the population that they will be hospitalized with Covid-19. Vaccination rates have fallen off for the former group, who are also most likely to die from an infection, and they were never strong to begin with for the latter”
…
“The known unknowns for the future, which could spur another round of investment and interest in updated Covid-19 vaccines, are biological. The virus has been evolving and will continue to evolve and could, in theory, reach a point where the current vaccines are ineffectual.
The other question mark is inside of us. The reason many people still enjoy protection from serious illness is because our body’s T-cells are familiar with the virus and can activate when they detect it. They may not be able to stop an infection entirely (that is the role of antibodies, which are quicker to fade) but they can stamp out the virus before a person becomes too sick.
What we don’t know today is how long our T cells’ memory will last, and how durable that immunity really is. The only way to find out is for more time to pass.”
“Some portion of this steep rise in cases is related to the fact that more people are being tested for the flu than in previous years. Over the month of November, about twice as many flu tests were done at clinical labs nationwide as during the same period last year (about 540,000 versus 265,000). More testing means more cases will get picked up.
However, there are corroborating warning signs that this is truly a bad season. Flu hospitalizations have been off the charts and are rising quickly. In a press conference Monday, CDC director Rochelle Walensky said there have already been 78,000 flu hospitalizations this season, or nearly 17 out of every 100,000 Americans. That’s “the highest we’ve seen at this time of year in a decade,” she said. In keeping with past trends, the highest hospitalization rates are among adults 65 and older.
What’s making these high hospitalization rates particularly concerning is their overlap with surges in other viruses causing many people to get sick enough to require admission. One of those is RSV, which has been packing pediatric hospitals for more than six weeks. And while Walensky noted there were signals RSV transmission was slowing in parts of the country, Covid-19 hospitalizations recently began to tick upward.”
“The worldwide monkeypox outbreak began in early May 2022. Since then, more than 15,000 cases of monkeypox have been identified across more than 60 countries. Disease caused by the monkeypox virus typically involves a few days of fever and lymph node swelling followed by a rash, which can leave scars. Most cases in the current outbreak have resolved without hospitalization or the need for medication. As of July 20, there have been five deaths, all of them in Africa.
Monkeypox is related to the smallpox virus, and immunity to smallpox is protective against monkeypox. But as of 1980, smallpox has been eradicated in humans, and vaccinations against smallpox have grown rare — and human cases of monkeypox have been on the rise.
With monkeypox, the world faces a very different situation than in the early days of Covid-19. Monkeypox, unlike SARS-CoV-2, is a known quantity. We have more tools to prevent and treat it — far more than we did for Covid-19 at the outset of the pandemic — and both public health and the general public have had a lot of practice taking measures to prevent infections from spreading.”
“We’re up to about 3,600 known cases of monkeypox in the United States, according to the Centers for Disease Control and Prevention (CDC). That’s more than double the number of cases from just two weeks ago.
As the federal government struggles to distribute vaccines where they’re needed, The Washington Post reports that the White House is thinking of declaring a public health emergency and naming a “White House coordinator” to oversee the response.
The public response should be: Please don’t. Please just get the vaccines to local public health agencies and let them deal with it. Because right now, that’s about half the problem that’s causing monkeypox to spread.
Red tape from the Food and Drug Administration (FDA) and the CDC left more than a million monkeypox vaccine doses stuck in storage in Denmark, and then another roll of red tape made it incredibly difficult for doctors to prescribe an alternative monkeypox treatment because it’s still in clinical trials.
As a result, local health agencies have had to carefully portion out vaccines to the highest-risk citizens—and they’re still running out. In Los Angeles, the county Public Health Department will only administer to people who are infected, people who have had high-risk contact (typically sex) with somebody who is infected, and then gay or bisexual men or trans people who fit in one of the [certain] categories”
…
“Fortunately, monkeypox’s spread has still remained pretty limited even as it has grown. The percentage of growth seems huge because we’re dealing with a fairly low baseline. And though monkeypox is not technically a sexually transmitted disease—it is spread through contact with the rashes and lesions created by the virus as well as through saliva—this particular version of monkeypox has been pretty resistant so far to being spread through methods other than sexual contact.”
“Critics — including researchers who study biosecurity and biosafety — argue it doesn’t really pass a cost-benefit analysis. In some ways, virus hunting is looking for a needle in a haystack — the handful of viruses that might cross over to humans amid tens of thousands that won’t — when we don’t even know how to tell needles from hay, or what to do with a needle once we identify one.
And some experts are raising another, even sharper question: What if viral discovery is not just an ineffective tactic but a terrible idea, one that might not only fail to prevent the next pandemic but potentially even make it more likely?”
…
“Monitoring the interface between humans and animals for pandemic prevention has value, particularly when the programs are narrowly targeted at certain objectives: say, a focus on reducing spillover, or surveillance of potential animal infections, or studying viruses that have already spilled over into humans. Research published last month in Nature projects that global warming could drive 4,000 viruses to spread for the first time between mammals, including potentially humans and animals, by 2070, underscoring the changing threat from zoonotic spillovers.
But if the risks of virus hunting are higher than the odds of a virus crossing over into humans and sparking a pandemic naturally, then viral discovery doesn’t just look inefficient. It looks like a bad idea.”
“But it’s one thing to come up with a vaccine, and entirely something else to manufacture it on a mass scale. That’s where the world has stumbled and where concerted planning now can make sure we’re prepared for the future. If we’re to have a better chance to fight the next pandemic — and there will be a next one — the US needs to build on these vaccine tech innovations and make investments to establish permanent facilities producing mRNA and adenovirus vaccines.”
…
“that slack won’t arrive naturally.
Weber, the former assistant secretary of defense for biodefense, has pushed for what he dubs a “10 + 10 Over 10” plan to prevent biological threats in the future. It is essentially a big government investment that could enable the kind of infrastructure necessary to have gotten to full vaccine availability in the US in, say, one or two months, not five.
The plan calls for $10 billion in additional annual funding for the Department of Defense, and another $10 billion per year for the Department of Health and Human Services, devoted to anticipating pandemic and other biological risks, for at least 10 years.
With that funding, government could finance the infrastructure for year-round vaccine manufacture.”
…
“The key is that these facilities need to be active during non-pandemic times, otherwise their expertise and readiness could deteriorate.”
…
“Pharmaceutical companies are not going to go this big on their own, and there’s no guarantee that the government will fund them sufficiently without pressure. In 2020 — during the pandemic — the Trump administration cut the DOD’s chemical and biodefense programs by 10 percent, with much of the cuts going to the vaccine component of the budget. To set this vision in motion, the US needs to not just reverse cuts like that but spend much more, in line with Weber’s $20 billion per year proposal.”